ResMed Announces FY 2027 Revenue Guidance and Shareholder Return Targets
ResMed (RMD) reported strong performance for the first quarter of fiscal year 2027, highlighted by a 7% revenue growth on a core constant currency basis. The company's management expressed confidence in its long-term trajectory, providing a robust revenue outlook for the full fiscal year 2027. For the upcoming fiscal year, ResMed projects total revenue to fall between $5.75 billion and $5.85 billion. Additionally, the company has committed to returning more than $1.85 billion to shareholders through various capital allocation methods, signaling strong cash flow generation and a commitment to shareholder value.
Tickers: $RMD
Topics: fiscal year results management commentary revenue growth
Read the full article at Seeking Alpha
Part of the story ResMed Reports Q1 Fiscal 2027 Growth Driven by Manufacturing Efficiency and GLP-1 Synergy (4 articles)